Oppenheimer Asset Management Inc. Sells 1,052 Shares of Solventum Co. (NYSE:SOLV)

Oppenheimer Asset Management Inc. decreased its position in shares of Solventum Co. (NYSE:SOLV) by 17.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,840 shares of the company’s stock after selling 1,052 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Solventum were worth $320,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. New York Life Investment Management LLC lifted its holdings in Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after purchasing an additional 136 shares in the last quarter. Blue Trust Inc. lifted its holdings in Solventum by 2.1% during the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock worth $549,000 after purchasing an additional 161 shares in the last quarter. MML Investors Services LLC lifted its holdings in Solventum by 3.2% during the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its holdings in Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares in the last quarter. Finally, Savant Capital LLC lifted its holdings in Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock worth $259,000 after purchasing an additional 233 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $75.69 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The firm has a market capitalization of $13.08 billion and a P/E ratio of 27.52. The business has a fifty day moving average of $73.42 and a 200 day moving average of $70.42.

Analyst Ratings Changes

A number of analysts recently issued reports on SOLV shares. Wells Fargo & Company increased their price objective on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Mizuho raised their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday. Bank of America raised their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Morgan Stanley raised their price target on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, The Goldman Sachs Group raised their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.